Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
University of Michigan Rogel Cancer Center.
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020.
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.
NCCN 免疫治疗相关毒性管理指南旨在为癌症免疫治疗相关免疫相关不良事件的管理提供指导。NCCN 免疫治疗相关毒性管理专家组是一个由 NCCN 成员机构代表组成的跨学科小组，成员包括来自广泛疾病部位的医学和血液肿瘤科医生，以及来自皮肤科、胃肠病学、内分泌学、神经肿瘤学、肾脏病学、心脏肿瘤学、眼科学、肺病学和肿瘤护理学等领域的专家。本期内容是管理嵌合抗原受体 T 细胞疗法相关毒性的建议摘录，并对现有证据进行了回顾。如需查看包括免疫检查点抑制剂相关毒性管理建议在内的 NCCN 指南全文，请访问 NCCN.org。
